| |
N
|
HR (95%CI)
|
P
|
I2, %
|
P(Heterogeneity)
|
|---|
|
MACE overall
|
7
|
2.273 (1.581–3.268)
|
< 0.001
|
60
|
0.02
|
|
Other
|
2
|
2.769 (1.630–4.706)
|
< 0.001
|
67.5
|
0.079
|
|
PMI
|
3
|
2.861 (1.835–4.460)
|
< 0.001
|
0
|
0.604
|
|
SMI/height squared
|
2
|
1.319 (0.570–3.050)
|
0.518
|
68.2
|
0.076
|
|
Prospective cohort
|
4
|
2.232 (1.278–3.898)
|
0.005
|
78.8
|
0.003
|
|
Retrospective cohort
|
3
|
2.315 (1.460–3.670)
|
< 0.001
|
0
|
0.665
|
|
CAD
|
3
|
1.979 (0.984–3.983)
|
0.056
|
84.2
|
0.002
|
|
Non-STEMI
|
1
|
3.320 (1.727–6.381)
|
< 0.001
| | |
|
CABG
|
1
|
1.960 (0.827–4.644)
|
0.126
| | |
|
Heart valve surgery
|
1
|
3.210 (1.374–7.501)
|
0.007
| | |
|
STEMI
|
1
|
2.060 (1.011–4.196)
|
0.046
| | |
|
Late mortality
|
3
|
2.152 (0.887–5.223)
|
0.09
|
91
|
< 0.001
|
|
Heart valve surgery
|
2
|
1.548 (0.7–3.422)
|
0.281
|
85.2
|
0.009
|
|
CABG
|
1
|
4.250 (2.181–8.283)
|
< 0.001
| | |
|
Death, HF-related hospitalization
|
2
|
1.370 (0.594–3.164)
|
0.459
|
62
|
0.105
|
|
All-cause mortality
|
2
|
1.354 (0.143–12.842)
|
0.792
|
90.5
|
0.001
|
- HR hazard ratio, CI confidence interval, MACE major adverse cardiovascular event, PMI psoas muscle area index, SMI skeletal muscle area index, CAD coronary artery disease, STEMI ST-elevated myocardial infarction, CABG coronary artery bypass graft, HF heart failure
